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Abstract
Cardiotoxicity is among the top drug safety concerns, and is of specific interest in tuberculosis, where this is a known or
potential adverse event of current and emerging treatment regimens. As there is a need for a tool, beyond the QT interval,
to quantify cardiotoxicity early in drug development, an empirical decision tree based classifier was developed to predict
the risk of Torsades de pointes (TdP). The cardiac risk algorithm was developed using pseudo-electrocardiogram (ECG)
outputs derived from cardiac myocyte electromechanical model simulations of increasing concentrations of 96 reference
compounds which represented a range of clinical TdP risk. The algorithm correctly classified 89% of reference compounds
with moderate sensitivity and high specificity (71 and 96%, respectively) as well as 10 out of 12 external validation
compounds and the anti-TB drugs moxifloxacin and bedaquiline. The cardiac risk algorithm is suitable to help inform early
drug development decisions in TB and will evolve with the addition of emerging data.
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Abbreviations
ADTree Alternating decision tree
APD Action potential duration
BDMM Biophysically-detailed myocyte models
CAD Cationic amphiphilic drug
CDISC Clinical trial data interchange standards
consortium
CPTR Critical path to TB drug regimen initiative
CSS Cardiac safety simulator
DDI Drug-drug interaction
ECG Electrocardiogram
EMW Electromechanical window
hERG Human ether-a-go–go-related gene
ORD O’Hara-Rudy models
PBPK Physiologically based pharmacokinetics
PD Pharmacodynamics
PK Pharmacokinetics
QTc Heart rate corrected QT interval
ROC Receiver-operator curve
RR Time gap between the peaks of the QRS
complex of the ECG wave
TB Tuberculosis
TdP Torsade de pointes
WEKA Waikato environment for knowledge analysis
Introduction
The need for new drugs against tuberculosis
Tuberculosis (TB) is a condition that affects one-quarter of
the world’s population, causing 1.5 million TB-related
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deaths per year and remains the leading world-wide cause
of death due to an infectious disease [1]. Due to the pro-
tracted duration of anti-TB therapy, combination drug
regimens are needed that enable a shorter treatment dura-
tion while maintaining an acceptable safety profile. This
necessitates both a robust drug development pipeline, as
well as an improved drug development process. Drug
development tools that provide improved predictions of
efficacy and safety for combination regimens are expected
to enhance the efficiency of regimen development process
by informing key decisions.
Since its inception in 2010, the critical path to TB drug
regimen (CPTR) initiative, a global public–private-part-
nership, has keenly focused on accelerating the develop-
ment of an entirely novel, shorter duration therapy for TB
[2]. A core aspect of CPTR’s strategy is the development,
validation and refinement of a suite of pre-clinical, trans-
lational methodologies and quantitative drug development
platforms. These efforts are focused on optimizing the
translation of novel TB drugs by leveraging integrated and
standardized data to develop first-in-class translational
methodologies, including the cardiac risk algorithm pre-
sented in this manuscript.
Efficient drug safety assessment
during development
Characterization of drug safety, equally with drug efficacy,
is critical during the drug development process. Prior to
human testing, non-clinical safety pharmacology and tox-
icology studies are conducted to predict compound risks in
humans, focusing on the risk of rare lethal events [3].
Despite extensive non-clinical testing, toxicological and
safety-related issues are the most common reasons for drug
candidate attrition up to Phase 2 [4]. Cardiotoxicity and
hepatotoxicity are among the top safety concerns, yet
comprehensive, detailed data on these toxicities is still
sparse in the public space [5, 6]. While the latter is a
common toxicity of anti-TB therapy, especially for first-
line drugs like isoniazid and rifampicin [7], electrophysi-
ological disruption of cardiac activity represents another
main concern for drug development in general, and for
anti-TB drug development specifically.
Torsade de pointes (TdP) is a syndrome of polymorphic
ventricular arrhythmia occurring in the setting of marked
prolongation of the QT interval as assessed by electrocar-
diogram (ECG). In TdP the QT interval is prolonged in the
heartbeats before the sudden onset of rapid and disorga-
nized contractions of the heart. Patients with TdP experi-
ence dizziness or loss of consciousness if the arrhythmia is
brief. If sustained, TdP can be lethal. Certain clinical
conditions which prolong the QT interval, such as con-
genital long QT syndrome or the administration of drugs
that block cardiac potassium channels, are often associated
with TdP, although it may not manifest at the time QT
prolongation is observed. Given this association, the
occurrence of post-dose QT prolongation is a commonly
used biomarker to identify drugs that could result in
iatrogenic TdP.
There is growing awareness that QT or heart-rate cor-
rected QT interval (QTc) prolongation is a limited or
incomplete biomarker of TdP risk. In some cases, QT
prolongation secondary to drug administration is not an
accurate indicator of TdP risk and therefore may not be
informative in the context of drug development [8].
Sponsors, academicians, and regulators agree that a more
comprehensive characterization of risk, based on complete
cardiac ion channel profiles and thorough quantification of
electrophysiological effects, may provide better concor-
dance between ECG signals and TdP risk [9, 10].
To help address this challenge, multiple classification
models were proposed recently using various, often
heterogenic sets of data representing a range of input
variables [11–13]. A more comprehensive analysis of
clinical data to enhance the current ECG assessment was
recently proposed by Johannesen and colleagues [14]. They
hypothesized that the effects of multichannel drug block
can be described by the thorough analysis of early repo-
larization (J–Tpeak; the duration between the J point and the
peak of the T wave) and late repolarization (Tpeak–Tend; the
duration between the peak and the end of the T wave). In a
clinical study led by Johannesen, four drugs were given to
22 healthy volunteers, dofetilide (a pure human ether-a-go–
go-related gene (hERG) potassium channel blocker),
quinidine, ranolazine, and verapamil (as drugs that block
hERG and either calcium or late sodium currents). The
results showed that a more thorough ECG-based charac-
terization of multichannel drug effects on human cardiac
repolarization may improve the assessment of drug-related
cardiac electrophysiology disruption.
Rationale of the project and aim of the study
Given the reliance on drug combinations for effective TB
treatment and the large proportion of standard anti-TB
agents which are known or suspected to be torsadogenic, a
robust cardiac safety testing platform should be utilized in
the development of new and novel anti-TB agents. This
study details the development of component of a quanti-
tative cardiac safety testing platform, which was conducted
according to four specific aims:
1) Collate available clinical and non-clinical data per-
taining to adverse cardiovascular effects and associ-
ated clinical outcomes of anti-TB drugs (and their
metabolites) when used individually and in
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combination (e.g., cardiac ion channel activity pro-
files, repolarization reserve effects—QT changes,
T-wave morphology changes, autonomic tone
effects, TdP, sudden death, hospitalization, etc.);
2) Develop an empirical TdP risk assessment model for
single chemical moieties;
3) Incorporate subject-level electrophysiological data
with complete ion channel activity profiles of QT-
prolonging drugs into a quantitative tool for use in
the development of comprehensive algorithms char-
acterizing cardiac arrhythmia risk profiles for anti-
TB drug combinations;
4) Inform experimental designs (in vitro, preclinical,
and clinical), data analytics, signal interpretation, and
go/no-go decisions related to cardiac arrhythmia risk
in the context of anti-TB drug combination
development.
The purpose of the work presented herein is to provide
drug developers with a tool for use early in anti-TB drug
development, to better quantify the risk of TdP utilizing
in vitro ion current inhibition results in combination with
human PK. Specifically, this report summarizes Aims 1 and
2 outlined above; namely, the development of an in silico
model, the cardiac risk algorithm, an empirical classifier
for single chemical moieties intended to support quantita-
tive TdP risk assessment, based on the cardiac electro-
physiology of human left ventricular cardiomyocytes along
with a quantitative assessment of TdP risk.
Methods
The centerpiece of the Cardiac Risk Algorithm is the in
silico model of the ventricular myocyte as implemented in
the Simcyp cardiac safety simulator (CSS 2.0, Simcyp,
Certara). The CSS includes two biophysically-detailed
myocyte models (BDMM) describing electrophysiology of
the human left ventricular cardiomyocytes which are con-
sidered to represent state-of-the-art models based on the
Hodgkin-Huxley action potential formalism [15, 16]. The
model by ten Tusscher (tT04) represents the default [17].
Additionally, the updated ten Tusscher (tT06) and O’Hara-
Rudy models (ORD) [18, 19] were also implemented. Both
models were developed from data derived predominantly
(tT) or exclusively (ORD) from experiments using human
myocytes. The forward Euler method is employed to
integrate model equations.
CSS operates on two levels, simulating either single cell
electrophysiology and outputting action potential and its
derivatives (APD50, APD90) or simulating a one-dimen-
sional string of cells, where the output is a pseudoECG
(viz. an in silico ECG) and its derivatives (e.g., QRS, QT).
In the latter case, as a one-dimensional fiber of car-
diomyocytes is heterogeneous in character, to mimic the
human heart, CSS has a left ventricular wall thickness
comprised by default of 50% endocardial, 30% midmy-
ocardial and 20% epicardial cells. All other physiological
parameters describe virtual individuals, using known car-
diomyocyte morphometric parameters (volume, area,
electric capacitance). Plasma ion concentration (K?, Na?,
Ca2?) and heart rate are specific for healthy individuals
[25–27]. CSS accounts for intra-individual circadian vari-
ability in physiological parameters (e.g., heart rate, plasma
ion concentrations) [28]. Every element of the CSS system,
including physiological parameters and their variability,
was obtained from the scientific literature as reported in a
peer reviewed publication or white paper [20]. CSS has
itself been validated in a growing number of publications
[15, 21, 22]. The CSS predictive performance was based on
the comparison of the simulated and clinically observed
endpoints (e.g., action potential duration [APD], QT, QRS)
[23].
Data inputs required for the CSS are as follows:
1) Nonclinical ionic channel inhibitory effects as mea-
sured by patch clamp assay (i.e., IC50 values for
rapidly activating delayed rectifier potassium current
IKr (encoded by hERG gene), delayed rectifier
potassium current IKs (encoded by KvLQT1/mink
gene), peak sodium current INa (encoded by Nav1.5
gene), L-type calcium current ICa (encoded by
Cav1.2 gene) and other currents if available);
2) Drug concentrations of parent and/or active metabo-
lites and/or concomitantly given drugs as obtained
from clinical studies or simulated using the Simcyp
physiologically based pharmacokinetic (PBPK)
model; and
3) Subject specific covariates affecting cardiac myocyte
APD or drug exposure (i.e., volume of cardiac
myocytes, sarcoplastic reticulum volume, cardiomy-
ocytes electric capacitance, plasma ions concentra-
tion, heart rate) [25–27].
Drug effects on four main ion channels were simulated
with a simple pore block model. All input data for the
drugs provided in this manuscript are available in the
Supplementary files.
Available outputs from the Simcyp CSS module
include:
1) Single cell action potential and its derivatives
(APD50, APD90—the time needed for 50 and 90%
of the cell repolarization)
2) PseudoECG signal and its derivatives (QRS, QT/
QTc, J-Tpeak, and Tpeak - Tend)
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3) Electro-mechanical window (time gap between the
end of electric and mechanical systole)
These outputs were utilized to develop models of
proarrhythmic potency (cardiac risk algorithms) for single
drugs or drug combinations. Multiple machine learning
algorithms implemented in the Waikato environment for
knowledge analysis (WEKA) were tested during model
development, including decision trees, random forests, and
support vector machines [24]. In all scenarios, the same
procedure was applied, namely the data set was randomly
divided to the learning set (90% of cases) and testing set
(10% of cases) in a tenfold cross validation procedure, and
eventually a validation set of 12 compounds was evaluated
using the best obtained model. The cardiac risk algorithm
output is continuous in the range\ 0;1[ and is inter-
preted as the probability of a compound lacking an asso-
ciation with TdP. A threshold of 0.5 was chosen as a
default value; therefore all results C 0.5 were classified as
negative and those\ 0.5 as positive (viz., TdP(-) and
TdP(?), respectively).
The analysis plan consisted of the following steps
(Fig. 1):
1) Stage 1: Development of cardiac risk algorithm
2) Stage 2: Evaluation of the cardiac risk algorithm on
validation dataset
3) Stage 3: Application of the proposed cardiac risk
algorithm to the chosen anti-TB drugs (moxifloxacin,
bedaquiline)
Data describing the in vitro measured inhibition of all
ionic channels were collected from the available literature
for 12 validation drugs and bedaquiline. This included
information about multiple ionic current inhibition mea-
sured via the patch clamp technique. All collected data are
provided in the supplementary materials (Supplementary
Table 1), including estimated IC50 values and detailed
descriptions of the measurement settings which differ for
the various ionic currents. The IC50 values applied during
the simulation study are marked in green and were selected
based on the assumption that the in vitro study should
mimic the in vivo human physiology as closely as possible.
The main parameters included: temperature, ion concen-
trations, and electric protocol (i.e., holding potential [mV],
depolarization potential [mV], repolarization potential
[mV], and measurement potential [mV]).
Simulations were performed in the CSS at the pseu-
doECG level in one female virtual individual, representa-
tive of the Caucasian population (viz. ‘‘PopRep’’), with 10
concentrations simulated for each drug (0, 0.0001, 0.001,
0.01, 0.1, 1, 10, 30, 100, and 500 lM). The randomly
derived physiological parameters characterizing the virtual
individual are listed below in Table 1 [25–29].
Additional endpoints for further analysis were simulated
using the CSS, including:
• QTc and/or QTc prolongation (difference between
baseline and drug modified QTc)
• QRS and/or QRS prolongation (difference between
baseline and drug modified QRS)
• Index of cardiac electrophysiological balance (iCEB; =
QT/QRS) [30]
• Electromechanical window (EMW) [31]
Input data
Ionic currents inhibion and
exposure informaon
Run simulaons
Simcyp Cardiac Safety Simulator (CSS) 
with biophysically detailed myocyte 
models (BDMM)
Compile simulaon results
PseudoECG signal and its derivaves 
(QRS, QT, J-Tpeak, Tpeak-Tend, and EMW)
Generate Cardiac Risk Algorithm 
Mulple machine learning techniques
Assess predicve performance
Clinical trial simulaons for comparison 
of observed and simulated data
Fig. 1 Model building schema
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For cardiac risk algorithm development, the learning set
consisted of 96 compounds (presented in Supplementary
material) and 12 compounds (Table 2) were used to assess
model predictive performance. All compounds were clas-
sified as TdP(?) or TdP(-) based on the CredibleMeds
QTdrugs classification as of November 2014 (Fig. 2,
Supplementary Table 1) [32, 33].
According to CredibleMeds, drugs are classified as:
1) Known Risk of TdP—these drugs prolong the QT
interval AND are clearly associated with a known
risk of TdP, even when taken as recommended (here
classified as TdP(?) or positive).
2) Possible Risk of TdP—these drugs can cause QT
prolongation BUT currently lack evidence for a risk
of TdP when taken as recommended (here classified
as TdP(-) or negative).
3) Conditional Risk of TdP—these drugs are associated
with TdP BUT only under certain circumstances of
their use (i.e., excessive dose, in patients with
conditions such as hypokalemia, or when taken with
interacting drugs) OR by creating conditions that
facilitate or induce TdP i.e., by inhibiting metabolism
of a QT-prolonging drug or by causing an electrolyte
disturbance that induces TdP (here classified as
TdP(-) or negative).
Drugs which were not mentioned in the CredibleMeds
listing were classified as TdP(-) or negative.
Among 96 compounds included in the learning dataset,
28 were classified as TdP(?) and 68 as TdP(-), whereas in
the validation dataset the TdP(?) and TdP(-) compounds
were balanced with 6 in each group (Fig. 2).
TB drugs of interest include moxifloxacin (Known Risk
of TdP - TdP(?)) as an element of the validation set and
bedaquiline (Possible Risk of TdP - TdP(-)) as a new
compound.
Results
The best model (Fig. 3) was developed with the use of an
alternating decision tree (ADTree) with input variables
including EM window and iCEB calculated across 10
Table 1 PopRep virtual individual characteristics
Parameter Value Unit
Age 34 Years
Plasma potassium concentration (K?) 5.49 mM
Plasma sodium concentration (Na?) 137.59 mM
Plasma calcium concentration (Ca2?) 2.25 mM
RR 808 ms
Cardiomyocyte volume 8183 lm3
Cardiomyocyte area 2274 lm2
Electric capacitance 60.42 pF
Sarcoplasmic reticulum volume 628.1 lm3
String length (heart wall thickness) 10.8 mm
Table 2 Validation drugs classification
Drug name CredibleMeds classification for TdP Risk Binary TdP classification
Fexofenadine Not mentioned Negative
Propafenone Not mentioned Negative
Verapamil Not mentioned Negative
Hydrodolasetron Possible risk of TdP (known association with QT prolongation, unknown association with TdP) Negative
Ranolazine Possible risk of TdP (known association with QT prolongation, unknown association with TdP) Negative
Vardenafil Possible risk of TdP (known association with QT prolongation, unknown association with TdP) Negative
Amiodarone Known risk of TdP (known association with TdP) Positive
Citalopram Known risk of TdP (known association with TdP) Positive
Clarithromycin Known risk of TdP (known association with TdP) Positive
Dofetilide Known risk of TdP (known association with TdP) Positive
Moxifloxacin Known risk of TdP (known association with TdP) Positive
Quinidine Known risk of TdP (known association with TdP) Positive
Learning set
96 compounds
28 – TdP(+)
68 – TdP(-)
Algorithm
development model
Validation set
12 compounds
6 – TdP(+)
6 – TdP(-)
External 
verificaon
Internal 
validaon
Predicve
performance
Fig. 2 Drugs classification and application in algorithm development
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concentrations/compound (encoded consecutively as
EMW1-10 and iCEB1-10) [34].
The model correctly classified the TdP propensity of 85
out of 96 learning set compounds as assessed by internal
validation procedures (89% accuracy), and 10 out of 12
compounds in the external validation set (83% accuracy).
Results are presented in Fig. 4, Panels A and B respec-
tively, whereas the receiver-operator curve (ROC) for the
learning set is shown in Fig. 5.
The incorrectly classified drugs from the learning data-
set are presented in Table 3. Of the compounds from the
validation set, the incorrectly classified drugs included
citalopram and quinidine which were both classified as
TdP(-) or non-proarrhythmic. Both anti-TB drugs of
interest were correctly classified according to their Credi-
bleMeds-based assessment, with moxifloxacin classified
as TdP(?) and bedaquiline classified as TdP(-) with a
high probability at 0.911.
Fig. 3 Drugs classification (from the WEKA classifier)
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Discussion
The cardiac risk algorithm describes the first step in the
development of a comprehensive cardiac safety assessment
platform to inform drug development decisions, in terms of
the potential torsadogenic risk of candidate anti-TB drugs.
This platform applies preclinical knowledge for different
types of compounds, in terms of their ion channel activity
and exposure–response relationships for electrophysiolog-
ical activity, to generate a binary classification as to the
potential risk of drug-induced TdP. As with any quantita-
tive drug development platform, the Cardiac Risk Algo-
rithm is intended to continuously evolve with additional
data.
While the algorithm itself is empirical, it was derived
from mechanistic information about multiple potentially
model
ADtree
learning set
96 compounds
28 – TdP(+)
68 – TdP(-)
internal
validaon
PREDICTED
TdP
(-)
TdP
(+)
O
BS
ER
VE
D TdP
(-)
65 3
TdP
(+)
8 20
ACC (accuracy) 0.885
TPR (sensivity) 0.714
TNR (specificity) 0. 956
PPV (precision) 0.884
ROC 0.958
validaon set
12 compounds
6 – TdP(+)
6 – TdP(-)
external
validaon
model
ADtree
PREDICTED
TdP
(-)
TdP
(+)
O
BS
ER
VE
D TdP
(-)
6 0
TdP
(+)
2 4
ACC (accuracy) 0.833
TPR (sensivity) 0.667
TNR (specificity) 1.00
PPV (precision) 0.875
ROC 0.819
A
B
Fig. 4 Results of the ADtree
model—internal and external
validation
Fig. 5 Receiver-operating curve
for learning set at varying
binary classification threshold
values
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affected channels and subsequent disruption of the elec-
trical and mechanical cardiac activity. To capture the
mechanistic model components, it was necessary to include
all available information on the concentration-dependent
inhibition of relevant cardiac ionic currents, which has
potential limitations given the heterogeneity of the input
data for the relevant parameters. Hence, strict criteria for
utilization of the IC50 values were proposed a priori to
reduce its influence on the simulation results and therefore
the model quality. The applied selection criteria were that
the in vitro study should mimic the in vivo human physi-
ology as closely as possible, and that the lowest IC50 value
should be applied. By applying these criteria, the mecha-
nistic model inputs are believed to have been selected
consistently, and albeit somewhat conservatively given the
selection of the lowest reported IC50 value.
Although this platform is ultimately intended to support
the assessment of novel and repurposed compounds for the
treatment of TB, a systematic approach was used to merge
in silico electromechanical simulations with observed
clinical TdP risk for a range of clinically-relevant drugs
across multiple therapeutic areas. This approach thereby
incorporates drugs representing a range of structural classes
with a broad spectrum of on- and off-target pharmacolog-
ical effects. Of the clinically and structurally diverse
compounds included in the 96 compound learning set, a
total of 11 compounds were misclassified, with 3 incor-
rectly predicted as TdP(?) and 8 incorrectly predicted as
TdP(-). In the former case, the three misclassified drugs,
gatifloxacin, sertindole, and tolterodine belong to different
therapeutic and structural classes and exhibited predicted
probabilities of 0.47, barely below the minimum TdP(-)
threshold value of 0.5. It is noted that since the time of
algorithm development, gatifloxacin (a fluoroquinolone
investigated for the treatment of TB) has been re-classified
by CredibleMeds as a TdP(?) drug, supporting its cor-
responding classification in the present work [35]. More-
over, the CredibleMeds classification of sertindole and
tolterodine as ‘‘Possible risk of TdP’’ is not necessarily
inconsistent with mid-range probabilities and it is possible
that, as in the case of gatifloxacin, additional clinical data
may result in reclassification of these agents. For example,
a sizeable proportion of sertindole-associated TdP cases
have been reported in the context of overdoses; whereas
tolterodine, as a CYP2D6 and CYP3A4 substrate, is a
potential candidate for drug–drug-interactions that could
contribute to TdP risk, although it remains to be seen if this
drug has a potential to cause TdP when exposure magni-
tudes do not surpass therapeutic levels [36, 37]. Using only
QT prolongation as the metric of TdP risk, 48 of the 96 test
compounds would have been classified as having a risk of
TdP whereas only 28 were truly associated with TdP. The
cardiac risk algorithm (CRA) performed substantially bet-
ter and appears to be a significant advance in assessing
cardiac safety.
The 8 drugs in the learning set that were incorrectly
classified as TdP(-) were structurally distinct, represented
a range of therapeutic classes, and also exhibited proba-
bilities of being TdP(-) close to the threshold value (range
0.57–0.66). Such ‘‘borderline’’ findings are not accounted
for when converting the Cardiac Risk Algorithm proba-
bilities to a binary TdP(?)/(-) classifier, and suggest that a
different threshold value and/or a more discrete classifi-
cation may be required.
The performance of the cardiac risk algorithm for the
validation set compounds classified verapamil, fexofe-
nadine, hydrodolasetron, vardenafil and ranolazine as
having a high probability ([ 0.8) of being TdP(-). The
classification is in concordance with the available literature
reports for verapamil, fexofenadine, and vardenafil, and it
is consistent with ranolazine’s current CredibleMeds
classification as being only a conditional risk drug [38–40].
Propafenone (which is not included in the CredibleMeds
database and thus was treated as TdP(-) in this analysis)
was also classified as lacking an association with TdP, but
with mid-range probability [0.65 for TdP(-), 0.35 for
Table 3 ADTree model
incorrectly classified drugs from
the learning dataset
Drug Observed Predicted TdP(?) probability TdP(-) probability
Gatifloxacin TdP(-) TdP(?) 0.535 0.465
Sertindole TdP(-) TdP(?) 0.535 0.465
Tolterodine TdP(-) TdP(?) 0.535 0.465
Chlorpromazine TdP(?) TdP(-) 0.342 0.658
Sotalol TdP(?) TdP(-) 0.364 0.636
Chloroquine TdP(?) TdP(-) 0.429 0.571
Disopyramide TdP(?) TdP(-) 0.429 0.571
Mesoridazine TdP(?) TdP(-) 0.429 0.571
Pentamidine TdP(?) TdP(-) 0.429 0.571
Probucol TdP(?) TdP(-) 0.429 0.571
Sparfloxacin TdP(?) TdP(-) 0.429 0.571
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TdP(?)]. This mid-range probability may be related to the
pharmacological properties of this agent, as it is classified
as a Class 1 antiarrhythmic and is known to be a moderate
QT prolonging agent. Interestingly, another Class 1
antiarrhythmic included in the learning set, disopyramide,
exhibited a similar probability of TdP(-) but was consid-
ered misclassified as it has a known risk of TdP according
to CredibleMeds. Thus, it is possible that propafenone
may best be considered as having a ‘‘probable risk of TdP’’,
consistent with its mid-range probability per the Cardiac
Risk Algorithm.
The two anti-TB drugs of interest, moxifloxacin and
bedaquiline, were correctly classified as TdP(?) and
TdP(-), respectively. Notably, moxifloxacin, a well-
known QT prolonger, exhibited a mid-range TdP(-)
probability of 0.46. While CredibleMeds classifies mox-
ifloxacin as TdP(?), this drug is considered to be relatively
safe as evidenced by its extensive use as a positive control
for thorough QT (TQT) trials [40, 41]. Therefore, the
probability predicted by the Cardiac Risk Algorithm seems
appropriate, and suggests that moxifloxacin could be
classified as a middle risk compound. Bedaquiline was
classified as TdP(-), consistent with the lack of TdP
reported in bedaquiline clinical trials [42].
Although the percentage of drugs misclassified by the
proposed Cardiac Risk Algorithm is small ([ 83% accu-
racy), it was considered that an alternative threshold value
for the binary classification may improve the classification.
However, the ROC analysis demonstrated that the thresh-
old TdP(-) probability value of 0.5 used in this study was
near optimal for the learning and testing sets of data. For
example, while 100% of true TdP(-) compounds in the
learning set can be correctly classified by decreasing the
threshold probability slightly to 0.47, there is no change in
the total number of incorrectly classified drugs as 11
known TdP(?) drugs are classified as TdP(-) with this
threshold. Further, this alternative threshold does not
modify the validation test results.
It may be logical to instead consider whether the results
suggest that there is a need for at least three risk categories.
From the observations, while it seems obvious that the
intermediate risk category would allow not only better
classification but also better risk assessment, the exact
threshold values for trinary classification are not clear.
More importantly, classification of the learning and vali-
dation set compounds as low, medium and high risk should
be done prior to model development, therefore the per-
formance of a more granular classification requires addi-
tional study. In the interim, the cardiac risk algorithm
classification of a compound as TdP(?)/(-) should be
interpreted along with its associated probability.
Finally, the predictive performance of any classification
model depends not only on the algorithm utilized for the
model development but also the data quality. Discussion
around the role of both elements is out of scope of the
current manuscript, yet it can be hypothesized that data
quality is at least equally, if not more, important than the
algorithm used. As was recently discussed, TdP risk clas-
sifications vary between sources and there is no conclusive
information on TdP risk for multiple known drugs [43]. It
is likely that alternative classifications for certain drugs,
such as those whose classification has been modified by
CredibleMeds could have changed the modeling results,
thereby highlighting an inherent risk of relying on a static
‘‘snapshot’’ of a dynamic classification system that is
continuously updated with gained clinical experience.
The main limitations of the present study are listed
below:
– A single chemical entity was utilized for the model
development; to analyze and predict the influence of
multiple chemicals (i.e., drugs and/or their metabo-
lites), and mechanistic models allowing for the
interaction
– In vitro data quality—heterogeneous sources were used
at the model development stage, all of them from the
publicly available literature
– Lack of non-drug parameters influencing drugs tor-
sadogenicity (i.e., interacting drugs, diseases, physio-
logical parameters and their variability).
In conclusion, an in silico modelling and simulation
approach that considered ECG changes beyond QT was
proposed as a tool for the cardiac safety assessment. The
cardiac safety simulator connected with the Simcyp plat-
form was used as the simulation platform. Despite the
potential sources of uncertainty, the combined PBPK-PD
model was able to reasonably extrapolate in vitro data to
the in vivo situation to predict clinical cardiac conse-
quences of drugs, including anti-TB agents. Such an
approach allows the testing of clinical scenarios early in
drug development programs, thus facilitating earlier go/no-
go decisions. This is of specific importance for the evalu-
ation of novel anti-TB drugs in development, given the
potential association of anti-TB agents with QT prolonga-
tion and the need for combination therapies for effective
treatment. Therefore, future work will expand this
methodology to support the selection of combination reg-
imen components based on overall TdP probability.
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